Lunac Therapeutics, a Leeds, England, UK-based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, raised £2.65M in funding in the first close of a Series A financing round.
The round was led by Epidarex Capital and the University of Leeds.
A spin out of the University of Leeds, Lunac is targeting activated Factor XII to identify and develop next-generation anticoagulants to overcome current therapies that carry the risk of causing bleeding. The company believes that targeting the coagulation cascade at the level of Factor XII – implicated in the formation of pathological clot formation, but not the stemming of bleeding – will reduce this risk.
The company was founded based on IP generated by Prof Helen Philippou and Dr Richard Foster, through insights built on a decade of academic research into Factor XII which has been supported by the Wellcome Trust, British Heart Foundation and the Medical Research Council.